Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05501639 · ClinicalTrials.gov registry record
Exacerbation Risk in Asthma
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 1,899
- Enrollment target
NCT05501639 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 1,899 participants.
The verdict
NCT05501639 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 1,899 participants
- Enrollment target
Study Summary
The purpose of this study is to conduct a comparative analysis of patients using Tiotropium in combination with Inhaled Corticosteroids (ICS) versus those that use long-acting β2-agonists (LABA) medication in combination with ICS.
Interventions
- DRUG tiotropium
- DRUG long-acting β2-agonists (LABA)
- DRUG inhaled corticosteroids (ICS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,899 participants |
| Start Date | 2021-05-14 |
| Est. Completion | 2021-11-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05501639
The ClinicalTrials.gov registry entry for NCT05501639 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,899 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which tiotropium is the first listed.
NCT05501639 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05501639 about?
NCT05501639 is a clinical study titled "Exacerbation Risk in Asthma". The purpose of this study is to conduct a comparative analysis of patients using Tiotropium in combination with Inhaled Corticosteroids (ICS) versus those that use long-acting β2-agonists (LABA) medication in combination with ICS.
What is the current status of trial NCT05501639?
This trial is currently completed. The enrollment target is 1,899 participants. The study started on 2021-05-14. Estimated completion is 2021-11-02.
What interventions are being tested in trial NCT05501639?
The interventions under investigation include: tiotropium (DRUG), long-acting β2-agonists (LABA) (DRUG), inhaled corticosteroids (ICS) (DRUG).
Who is sponsoring clinical trial NCT05501639?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.